Search

Your search keyword '"Swallow, Carol J"' showing total 477 results
Start Over Author "Swallow, Carol J"
477 results on '"Swallow, Carol J"'

102. Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG

Author

Houdt, Winan J., primary, Fiore, Marco, additional, Barretta, Francesco, additional, Rutkowski, Piotr, additional, Blay, Jean‐Yves, additional, Lahat, Guy, additional, Strauss, Dirk, additional, Gonzalez, Ricardo J., additional, Ahuja, Nita, additional, Grignani, Giovanni, additional, Quagliuolo, Vittorio, additional, Stoeckle, Eberhard, additional, De Paoli, Antonino, additional, Schrage, Yvonne, additional, Cardona, Kenneth, additional, Pennacchioli, Elisabetta, additional, Pillarisetty, Venu G., additional, Nessim, Carolyn, additional, Swallow, Carol J., additional, Bagaria, Sanjay P., additional, Canter, Robert, additional, Mullen, John T., additional, Callegaro, Dario, additional, Fairweather, Mark, additional, Miceli, Rosalba, additional, Raut, Chandrajit P., additional, Gronchi, Alessandro, additional, and Gladdy, Rebecca A., additional

Published
2020
Full Text
View/download PDF

104. Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers

Author

Ma, Lucy X., primary, Espin-Garcia, Osvaldo, additional, Lim, Charles H., additional, Jiang, Di M., additional, Sim, Hao-Wen, additional, Natori, Akina, additional, Chan, Bryan A., additional, Suzuki, Chihiro, additional, Chen, Eric X., additional, Liu, Geoffrey, additional, Brar, Savtaj S., additional, Swallow, Carol J., additional, Yeung, Jonathan C., additional, Darling, Gail E., additional, Wong, Rebecca K., additional, Kalimuthu, Sangeetha N., additional, Conner, James, additional, Elimova, Elena, additional, and Jang, Raymond W., additional

Published
2020
Full Text
View/download PDF

108. Influence of sarcopenia, clinical data, and 2-[18F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer.

Author

Anconina, Reut, Ortega, Claudia, Metser, Ur, Liu, Zhihui Amy, Suzuki, Chihiro, McInnis, Micheal, Darling, Gail E., Wong, Rebecca, Taylor, Kirsty, Yeung, Jonathan, Chen, Eric X., Swallow, Carol J., Bajwa, Jaspreet, Jang, Raymond W., Elimova, Elena, and Veit-Haibach, Patrick

Subjects
PROPORTIONAL hazards models, SARCOPENIA, ESOPHAGEAL cancer, LEAN body mass, ADENOCARCINOMA, PROGNOSIS, STATISTICS, MULTIVARIATE analysis, RISK assessment, RADIOPHARMACEUTICALS, POSITRON emission tomography, DEOXY sugars, PREDICTION models, ESOPHAGEAL tumors, DISEASE risk factors
Abstract

Purpose: To determine the prognostic value of sarcopenia measurements done on staging 2-[18F] FDG PET/CT together with metabolic activity of the tumor in patients with adenocarcinoma esophagogastric cancer with surgical treatment. Methods: Patients with early-stage, surgically treated esophageal adenocarcinoma and available pre-treatment 2-[18F] FDG PET/CT were included. The standard uptake value (SUV) and SUV normalized by lean body mass (SUL) were recorded. Skeletal muscle index (SMI) was measured at the L3 level on the CT component of the PET/CT. Sarcopenia was defined as SMI < 34.4cm2/m2 in women and < 45.4cm2/m2 in men. Results: Of the included 145 patients. 30% were sarcopenic at baseline. On the univariable Cox proportional hazards analysis, ECOG, surgical T and N staging, lymphovascular invasion (LVI) positive lymph nodes, and sarcopenia were significant prognostic factors concerning RFS and OS. On multivariable Cox regression analysis, surgical N staging (p = 0.025) and sarcopenia (p = 0.022) remained significant poor prognostic factors for OS and RFS. Combining the clinical parameters with the imaging-derived nutritional evaluation of the patient but not metabolic parameters of the tumor showed improved predictive ability for OS and RFS. Conclusion: Combining the patients' imaging-derived sarcopenic status with standard clinical data, but not metabolic parameters, offered an overall improved prognostic value concerning OS and RFS. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

110. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group.

Author

Swallow, Carol J., Strauss, Dirk C., Bonvalot, Sylvie, Rutkowski, Piotr, Desai, Anant, Gladdy, Rebecca A., Gonzalez, Ricardo, Gyorki, David E., Fairweather, Mark, van Houdt, Winan J., Stoeckle, Eberhard, Park, Jae Berm, Albertsmeier, Markus, Nessim, Carolyn, Cardona, Kenneth, Fiore, Marco, Hayes, Andrew, Tzanis, Dimitri, Skoczylas, Jacek, and Ford, Samuel J.

Abstract

Background: Retroperitoneal soft tissue sarcomas comprise a heterogeneous group of rare tumors of mesenchymal origin that include several well-defined histologic subtypes. In 2015, the Transatlantic Australasian RPS Working Group (TARPSWG) published consensus recommendations for the best management of primary retroperitoneal sarcoma (RPS). Since then, through international collaboration, new evidence and knowledge have been generated, creating the need for an updated consensus document. Methods: The primary aim of this study was to critically evaluate the current evidence and develop an up-to-date consensus document on the approach to these difficult tumors. The resulting document applies to primary RPS that is non-visceral in origin, with exclusion criteria as previously described. The relevant literature was evaluated and an international group of experts consulted to formulate consensus statements regarding the best management of primary RPS. A level of evidence and grade of recommendation were attributed to each new/updated recommendation. Results: Management of primary RPS was considered from diagnosis to follow-up. This rare and complex malignancy is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, and an individualized management plan should be made based on the 29 consensus statements included in this article, which were agreed upon by all of the authors. Whenever possible, patients should be enrolled in prospective trials and studies. Conclusions: Ongoing international collaboration is critical to expand upon current knowledge and further improve outcomes of patients with RPS. In addition, prospective data collection and participation in multi-institution trials are strongly encouraged. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

111. Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma

Author

Jiang, Di M., primary, Suzuki, Chihiro, additional, Espin‐Garcia, Osvaldo, additional, Lim, Charles H., additional, Ma, Lucy X., additional, Sun, Peiran, additional, Sim, Hao‐Wen, additional, Natori, Akina, additional, Chan, Bryan A., additional, Moignard, Stephanie, additional, Chen, Eric X., additional, Liu, Geoffrey, additional, Swallow, Carol J., additional, Darling, Gail E., additional, Wong, Rebecca, additional, Jang, Raymond W., additional, and Elimova, Elena, additional

Published
2020
Full Text
View/download PDF

113. Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG

Author

Raut, Chandrajit P., primary, Callegaro, Dario, additional, Miceli, Rosalba, additional, Barretta, Francesco, additional, Rutkowski, Piotr, additional, Blay, Jean-Yves, additional, Lahat, Guy, additional, Strauss, Dirk C., additional, Gonzalez, Ricardo, additional, Ahuja, Nita, additional, Grignani, Giovanni, additional, Quagliuolo, Vittorio, additional, Stoeckle, Eberhard, additional, De Paoli, Antonino, additional, Pillarisetty, Venu G., additional, Nessim, Carolyn, additional, Swallow, Carol J., additional, Bagaria, Sanjay, additional, Canter, Robert, additional, Mullen, John, additional, Gelderblom, Hans J., additional, Pennacchioli, Elisabetta, additional, van Coevorden, Frits, additional, Cardona, Kenneth, additional, Fiore, Marco, additional, Fairweather, Mark, additional, and Gronchi, Alessandro, additional

Published
2019
Full Text
View/download PDF

114. Improving outcomes in resectable gastric cancer: a review of current and future strategies

Author

Chan, Bryan A., Jang, Raymond W., Wong, Rebecca K.S., Swallow, Carol J., Darling, Gail E., and Elimova, Elena

Subjects
Care and treatment, Evaluation, Stomach cancer -- Care and treatment, Medical care quality -- Evaluation, Medical care -- Quality management
Abstract

Introduction Despite the declining incidence of gastric cancer, it remains the fifth most common malignancy worldwide--with 951,000 new cases in 2012--and represents nearly 7% of all cancer. The majority of [...], Gastric cancer is a highly fatal malignancy, and surgery alone often does not provide a cure, even for relatively early stages of disease. Various approaches have been adopted around the world to improve surgical outcomes; however, there currently is no global consensus with regard to the extent of surgery or the timing and choice of chemotherapy and radiation. Here we review the evidence supporting current approaches to resectable gastric cancer, including discussion of the optimal extent of surgery and lymphadenectomy, adjuvant chemotherapy, postoperative chemotherapy with chemoradiation, and perioperative chemotherapy. Additionally, we discuss novel approaches, including intensified chemotherapy (in neoadjuvant, perioperative, and adjuvant settings), pre- and postoperative chemoradiation in combination with chemotherapy, and the role of biologics and targeted therapy. Finally, we examine the promise of molecular subtyping and potential biomarkers for improved patient selection. Upcoming and future trials should help answer questions regarding the optimal sequencing and choice of treatments, in order to further improve survival and move us towards ultimately curing more patients with resectable gastric cancer.

Published
2016

119. Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group

Author

Haas, Rick L. M., primary, Bonvalot, Sylvie, additional, Miceli, Rosalba, additional, Strauss, Dirk C., additional, Swallow, Carol J., additional, Hohenberger, Peter, additional, van Coevorden, Frits, additional, Rutkowski, Piotr, additional, Callegaro, Dario, additional, Hayes, Andrew J., additional, Honoré, Charles, additional, Fairweather, Mark, additional, Gladdy, Rebecca, additional, Jakob, Jens, additional, Szacht, Milena, additional, Fiore, Marco, additional, Chung, Peter W., additional, van Houdt, Winan J., additional, Raut, Chandrajit P., additional, and Gronchi, Alessandro, additional

Published
2019
Full Text
View/download PDF

120. Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.

Author

Ma, Lucy X., Taylor, Kirsty, Espin‐Garcia, Osvaldo, Anconina, Reut, Suzuki, Chihiro, Allen, Michael J., Honorio, Marta, Bach, Yvonne, Allison, Frances, Chen, Eric X., Brar, Savtaj, Swallow, Carol J., Yeung, Jonathan, Darling, Gail E., Wong, Rebecca, Kalimuthu, Sangeetha N., Jang, Raymond W., Veit‐Haibach, Patrick, and Elimova, Elena

Subjects
COMPUTED tomography, PROGNOSIS, ADENOCARCINOMA, METASTASIS, SARCOPENIA
Abstract

Background: Malnutrition and sarcopenia are poor prognostic factors in many cancers. Studies in gastric and esophageal (GE) cancer have focused on curative intent patients. This study aims to evaluate the prognostic utility of malnutrition and sarcopenia in de novo metastatic GE adenocarcinoma. Methods: Patients with de novo metastatic GE adenocarcinoma seen at the Princess Margaret Cancer Centre from 2010 to 2016 with an available pre‐treatment abdominal computed tomography (CT) were included. Malnutrition was defined as nutritional risk index (NRI) <97.5. Skeletal muscle index (SMI) was measured at the L3 level (sarcopenia defined as SMI <34.4 cm2/m2 in women and <45.4 cm2/m2 in men). Patients receiving chemotherapy had NRI and SMI recalculated at the time of first restaging CT. Results: Of 175 consecutive patients, 33% were malnourished and 39% were sarcopenic at baseline. Patients with pretreatment malnourishment had significantly shorter overall survival (OS; 5.8 vs. 10.9 months, p = 0.000475). Patients who became malnourished during chemotherapy had worse OS compared to those who maintained their nutrition (12.2 vs. 17.5 months p = 0.0484). On univariable analysis, ECOG (p < 0.001), number of metastatic sites (p = 0.029) and NRI (p < 0.001) were significant prognostic factors while BMI (p = 0.57) and sarcopenia (p = 0.19) were not. On multivariable analysis, ECOG (p < 0.001), baseline NRI (p = 0.025), and change in NRI during treatment (p < 0.001) were significant poor prognostic factors for OS. Conclusions: In de novo metastatic GE adenocarcinoma patients, ECOG, pretreatment NRI and change in NRI were significant prognostic factors for OS while sarcopenia was not. Use of NRI at baseline and during treatment can provide useful prognostic information. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

121. Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer.

Author

Jiang, Di Maria, Sim, Hao-Wen, Espin-Garcia, Osvaldo, Chan, Bryan A., Natori, Akina, Lim, Charles H., Moignard, Stephanie, Chen, Eric X., Liu, Geoffrey, Darling, Gail, Swallow, Carol J., Brar, Savtaj, Brierley, James, Ringash, Jolie, Wong, Rebecca, Kim, John, Rogalla, Patrik, Hafezi-Bakhtiari, Sara, Knox, Jennifer J., and Jang, Raymond W.

Subjects
THERAPEUTIC use of antineoplastic agents, CISPLATIN, COMBINED modality therapy, ESOPHAGEAL tumors, FLUOROURACIL, PATIENT aftercare, IDENTIFICATION, LONGITUDINAL method, MULTIVARIATE analysis, PACLITAXEL, PATIENTS, PROBABILITY theory, REGRESSION analysis, STOMACH tumors, SURVIVAL analysis (Biometry), TREATMENT effectiveness, PROPORTIONAL hazards models, RETROSPECTIVE studies, DESCRIPTIVE statistics, CARBOPLATIN, KAPLAN-Meier estimator, CHEMORADIOTHERAPY, EVALUATION
Abstract

Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alternatively, nCRT with cisplatin plus fluorouracil (CF) can be used. Definitive chemoradiotherapy (dCRT) with CP or CF can be used if surgery is not planned. In the absence of comparative trials, we aimed to evaluate outcomes of CP and CF in the settings of TMT and dCRT. Methods: A single-site, retrospective cohort study was conducted at the Princess Margaret Cancer Centre to identify all patients who received CRT for locoregional esophageal or GEJ cancer. Overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method and multivariable Cox regression model. The inverse probability treatment weighting (IPTW) method was used for sensitivity analysis. Results: Between 2011 and 2015, 93 patients with esophageal (49%) and GEJ (51%) cancers underwent nCRT (n = 67; 72%) or dCRT (n = 26; 28%). Median age was 62.3 years and 74% were male. Median follow-up was 23.9 months. Comparing CP to CF in the setting of TMT, the OS and DFS rates were similar. In the setting of dCRT, CP was associated with significantly inferior 3-year OS (36 vs. 63%; p = 0.001; HR 3.1; 95% CI: 1.2–7.7) and DFS (0 vs. 41%; p = 0.004; HR 3.6; 95% CI: 1.4–8.9) on multivariable and IPTW sensitivity analyses. Conclusions: TMT with CF and CP produced comparable outcomes. However, for dCRT, CF may be a superior regimen. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

123. Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma

Author

MacNeill, Andrea J., primary, Gronchi, Alessandro, additional, Miceli, Rosalba, additional, Bonvalot, Sylvie, additional, Swallow, Carol J., additional, Hohenberger, Peter, additional, Van Coevorden, Frits, additional, Rutkowski, Piotr, additional, Callegaro, Dario, additional, Hayes, Andrew J., additional, Honoré, Charles, additional, Fairweather, Mark, additional, Cannell, Amanda, additional, Jakob, Jens, additional, Haas, Rick L., additional, Szacht, Milena, additional, Fiore, Marco, additional, Casali, Paolo G., additional, Pollock, Raphael E., additional, Barretta, Francesco, additional, Raut, Chandrajit P., additional, and Strauss, Dirk C., additional

Published
2018
Full Text
View/download PDF

126. Not a broken heart

Author

Van Spall, Harriette GC, Roberts, Jason D., Sawka, Anna M., Swallow, Carol J., and Mak, Susanna

Published
2007

130. Post‐relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans‐Atlantic RPS Working Group

Author

MacNeill, Andrea J., primary, Miceli, Rosalba, additional, Strauss, Dirk C., additional, Bonvalot, Sylvie, additional, Hohenberger, Peter, additional, Van Coevorden, Frits, additional, Rutkowski, Piotr, additional, Callegaro, Dario, additional, Hayes, Andrew J., additional, Honoré, Charles, additional, Fairweather, Mark, additional, Cannell, Amanda, additional, Jakob, Jens, additional, Haas, Rick L., additional, Szacht, Milena, additional, Fiore, Marco, additional, Casali, Paolo G., additional, Pollock, Raphael E., additional, Raut, Chandrajit P., additional, Gronchi, Alessandro, additional, and Swallow, Carol J., additional

Published
2017
Full Text
View/download PDF

134. Canadian Society of Surgical Oncology Annual Scientific MeetingReal-time electromagnetic navigation in breast-conserving surgery: clinical feasibility study on palpable tumoursIntraoperative margin assessment in wire-localized breast-conserving surgery: a population-level comparison of techniquesGlove and instrument handling in cancer surgery: a survey of surgeons’ beliefs and practicesPrognostic factors in determining the outcome of head and neck cutaneous melanomaImpact of time from initial biopsy to definitive excision when residual melanoma is presentTotal neoadjuvant therapy for pancreatic cancer: an institutional experienceMyosteatosis visible on preoperative CT scan is associated with reduced survival following resection of periampullary adenocarcinomas

Author

Gauvin, Gabrielle, primary, Laws, Alison, primary, Berger-Richardson, David, primary, Buchko, Kristyn, primary, Nadler, Ashlie, primary, Aubin, Jean-Michel, primary, Ungi, Tamas, additional, Yeo, Caitlin T., additional, Lasso, Andras, additional, Rudan, John, additional, Walker, Ross, additional, Fichtinger, Gabor, additional, Engel, C. Jay, additional, Brar, Mantaj S., additional, Bouchard-Fortier, Antoine, additional, Leong, Brad, additional, Quan, May Lynn, additional, Govindarajan, Anand, additional, Gladdy, Rebecca A., additional, McCart, J. Andrea, additional, Swallow, Carol J., additional, Pathak, K. Alok, additional, Ruth, Karen J., additional, Farma, Jeffrey, additional, Reddy, Sanjay, additional, Zih, Francis S.W., additional, Hoffman, John, additional, Sigurdson, Elin, additional, Al-manasra, Tariq, additional, Tobola, Elizabeth, additional, Salazar, Santiago, additional, Leugner, Derek, additional, Sutherland, Francis R., additional, Ball, Chad, additional, Dixon, Elijah, additional, Baracos, Vickie, additional, and Bathe, Oliver F., additional

Published
2016
Full Text
View/download PDF

135. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS)

Author

Gronchi, Alessandro, primary, Strauss, Dirk C., additional, Miceli, Rosalba, additional, Bonvalot, Sylvie, additional, Swallow, Carol J., additional, Hohenberger, Peter, additional, Van Coevorden, Frits, additional, Rutkowski, Piotr, additional, Callegaro, Dario, additional, Hayes, Andrew J., additional, Honoré, Charles, additional, Fairweather, Mark, additional, Cannell, Amanda, additional, Jakob, Jens, additional, Haas, Rick L., additional, Szacht, Milena, additional, Fiore, Marco, additional, Casali, Paolo G., additional, Pollock, Raphael E., additional, and Raut, Chandrajit P., additional

Published
2016
Full Text
View/download PDF

136. Canadian Society of Surgical Oncology Annual General MeetingUrinary metabolomics of gastric cancerSentinel lymph node biopsy in thin melanoma: a systematic review and meta-analysisPreoperative neutrophil:lymphocyte ratio is a better prognostic serum biomarker than platelet:lymphocyte ratio in patients undergoing resection for nonmetastatic colorectal cancerPatient decision-making in palliative surgeryHospital readmission after surgery for gastric cancer: frequency, timing, etiologies and survivalClinical features and outcomes of 20 patients with desmoplastic small round cell tumourBiliary drainage procedures for palliation of extrahepatic cholangiocarcinomaLong-term outcomes following level-3 axillary lymph node dissection for breast cancerAdverse events related to lymph node dissection for cutaneous melanoma: a systematic review and meta-analysisCollaborative case conferences in rectal cancer: case series in a tertiary care centre

Author

Chan, Angela W., primary, Cordeiro, Erin, primary, Choi, Woo Jin, primary, Hamilton, Trevor D., primary, Merchant, Shaila J., primary, Angarita, Fernando A., primary, Turner, Benjamin T., primary, Poushay, Heather M., primary, Alabbas, Haytham H., primary, Eskicioglu, Cagla, primary, Broadhurst, David, additional, Mercier, Pascal, additional, Schiller, Daniel, additional, Eurich, Dean T., additional, Robbins, Sarah, additional, Sawyer, Michael B., additional, Gervais, Mai-Kim, additional, Shah, Prakesh, additional, Hong, Nicole Look, additional, Wright, Frances C., additional, Cleghorn, Michelle C., additional, Jiang, Haiyan, additional, Jackson, Timothy D., additional, Okrainec, Allan, additional, Quereshy, Fayez A., additional, Tsang, Melanie E., additional, Kim, Audrey, additional, Selby, Debbie, additional, Ituarte, Philip H.G, additional, Choi, Audrey, additional, Sun, Virginia, additional, Chao, Joseph, additional, Kim, Joseph, additional, Hassan, Saima, additional, Cannell, Amanda J., additional, Dickson, Brendan C., additional, Gladdy, Rebecca A., additional, Swallow, Carol J., additional, Hogg, David, additional, Gupta, Abha, additional, Blackstein, Martin E., additional, McCart, J. Andrea, additional, Bowes, Julia, additional, Fasola, Cynthia, additional, Ball, Chad, additional, Dixon, Elijah, additional, Sutherland, Francis R., additional, Bathe, Oliver F., additional, Hallet, Julie, additional, Look-Hong, Nicole, additional, Rodriguez-Rivera, Angel M., additional, Krotneva, Stanimira, additional, Chang, Sue-Ling, additional, Patakfalvi, Laura, additional, Landry, Tara, additional, Meguerditchian, Ari, additional, Amin, Nalin, additional, Cadeddu, Margherita, additional, Forbes, Shawn, additional, Kelly, Stephen, additional, Yang, Ilun, additional, Tsai, Scott, additional, Francescutti, Valerie, additional, Coates, Angela, additional, Grubac, Vanja, additional, Sonnandara, Ranil, additional, and Simunovic, Marko, additional

Published
2015
Full Text
View/download PDF

138. Gastrointestinal Stromal Tumours: Etiology, Pathology and Clinical Management

Author

Blackstein, Martin E, Dubé, Pierre, Fletcher, Jonathan A, Keller, Oliver R, Knowling, Margaret, Létourneau, Richard, Morris, Donald, Riddell, Robert, Rorke, Stewart, Swallow, Carol J, and Canadian Advisory Committee on GIST

Subjects
Article Subject
Abstract

Investigation of the regulation of cell growth, differentiation and death by signalling pathways has led to a greater understanding of how alterations in these pathways play a critical role in the development of some cancers, and has opened new opportunities for their treatment. In the present review, results with the prototype drug of this class, imatinib (Gleevec, Glivec [formerly STI571]; Novartis, Switzerland), in metastatic gastrointestinal stromal tumours are presented. The present review originated from a conference of the authors held in Montreal, Quebec in June 2003, under the sponsorship of Novartis.

Published
2004
Full Text
View/download PDF

139. Desmoid-Type Fibromatosis and Pregnancy

Author

Fiore, Marco, primary, Coppola, Sara, additional, Cannell, Amanda J., additional, Colombo, Chiara, additional, Bertagnolli, Monica M., additional, George, Suzanne, additional, Le Cesne, Axel, additional, Gladdy, Rebecca A., additional, Casali, Paolo G., additional, Swallow, Carol J., additional, Gronchi, Alessandro, additional, Bonvalot, Sylvie, additional, and Raut, Chandrajit P., additional

Published
2014
Full Text
View/download PDF

146. Suppression of Cancer Progression by MGAT1 shRNA Knockdown

Author

Beheshti Zavareh, Reza, primary, Sukhai, Mahadeo A., additional, Hurren, Rose, additional, Gronda, Marcela, additional, Wang, Xiaoming, additional, Simpson, Craig D., additional, Maclean, Neil, additional, Zih, Francis, additional, Ketela, Troy, additional, Swallow, Carol J., additional, Moffat, Jason, additional, Rose, David R., additional, Schachter, Harry, additional, Schimmer, Aaron D., additional, and Dennis, James W., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results